Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

What Was Tested

The paper reports a study of Semaglutide and Exenatide, published as a randomized controlled trial.

To assess the effect of baseline body mass index (BMI) and the occurrence of nausea and/or vomiting on weight loss induced by semalgutide, a once-weekly glucagon-like peptide 1 analogue for the treatment of type 2 diabetes.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Subjects were subdivided by baseline BMI and reporting (yes/no) of any nausea and/or vomiting.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.

Change from baseline in body weight was assessed within each trial and subgroup.

A mediation analysis separated weight loss into direct or indirect (mediated by nausea or vomiting) effects.

What Was Measured

PubMed files the paper under topics including Body Mass Index, Diabetes Mellitus, Type 2, Exenatide, Glucagon-Like Peptides, Hypoglycemic Agents, Insulin Glargine and Nausea.

Author keywords: BMI, GLP-1 analogue, GLP-1 based therapy, gastrointestinal adverse events, vomiting and weight control.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Semaglutide and Exenatide.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page and the Exenatide compound page.